Anna Vassilenko
A5056488187- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- HIV Research and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- COVID-19 Clinical Research Studies
- HIV, Drug Use, Sexual Risk
- Tuberculosis Research and Epidemiology
- Syphilis Diagnosis and Treatment
- Viral-associated cancers and disorders
- Liver Disease Diagnosis and Treatment
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- HIV/AIDS Impact and Responses
- Hepatitis B Virus Studies
- Optical Imaging and Spectroscopy Techniques
- Peptidase Inhibition and Analysis
- Pharmacological Receptor Mechanisms and Effects
- Chronic Myeloid Leukemia Treatments
- Infrared Thermography in Medicine
- Autoimmune Bullous Skin Diseases
- Drug-Induced Adverse Reactions
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 and healthcare impacts
Belarusian State Medical University
2010-2025
Rigshospitalet
2023
Statens Serum Institut
2023
University of Copenhagen
2023
RSPC MT
2021-2023
9th City Clinical Hospital
2016-2023
Medical University of Warsaw
2020
Vilnius University
2020
East Tallinn Central Hospital
2020
University of Banja Luka
2020
Improved methods for targeting HIV testing among patients most likely to be infected are required; HIDES I aimed define the methodology of a European wide study prevalence in individuals presenting with one eight indicator conditions/diseases (ID); sexually transmitted infection, lymphoma, cervical or anal cancer/dysplasia, herpes zoster, hepatitis B/C, mononucleosis-like illness, unexplained leukocytopenia/thrombocytopenia and seborrheic dermatitis/exanthema, identify those an >0.1%, level...
IntroductionThe SARS-CoV-2 pandemic has hit the European region disproportionately. Many HIV clinics share staff and logistics with infectious disease facilities, which are now on frontline in tackling COVID-19. Therefore, this study investigated impact of current situation care continuity antiretroviral treatment (ART) supplies CEE countries.MethodsThe Euroguidelines Central Eastern Europe (ECEE) Network Group was established February 2016 to review standards for region. The group consists...
European guidelines recommend the routine offer of an HIV test in patients with a number AIDS-defining and non-AIDS conditions believed to share association HIV; so called indicator (IC). Adherence this guidance across Europe is not known. We audited testing behaviour accessing care for ICs. Participating centres reviewed case notes either 100 or all consecutive one year, presenting each following ICs: tuberculosis, non-Hodgkins lymphoma, anal cervical cancer, hepatitis B C oesophageal...
Background It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) undiagnosed prevalence of at least 0.1%. Our aim was determine the for 14 different across 20 European countries. Methods Individuals aged 18–65 years presenting care one ICs between January 2012 and June 2014 were included routinely offered test. Logistic regression assessed factors associated testing positive. Patients infectious mononucleosis-like syndrome (IMS) recruited up until...
With no expected vaccine for HIV in the near future, we aimed to define current situation and challenges pre- post-exposure prophylaxis (PrEP PEP) Central Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited respond a 27-item survey including questions on PrEP (response rate 91.6%). was licensed 68.2%; 95 centers offered estimated number around 9000. It available daily (40.1%), on-demand (13.3%), or both forms (33.3%). access <1−80%. Three major barriers lack of...
Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prognostic role low CD4:CD8 ratio elevated CD8 cell counts the cancer remains unclear. We investigated association hazard non-AIDS defining malignancy (NADM), AIDS-defining (ADM) most frequent group cancers ART-treated people with HIV (PWH) a CD4 viral load measurements...
Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care HIV, antiretroviral treatment (ART) and virologically suppressed (VS), the aim of monitoring Continuum Care estimate efficacy programmes. We developed an estimation-tool, ESTIHIV, determined minimal required for a random sample, produce representative estimates, specified level precision, people ART VS. For proof concept, 8852 positive persons from seven different countries, follow-up visit during...
We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized pen-and-paper neuropsychological tests. NCI was defined as normalized Z score ≤−1 at least 2 out 5 cognitive domains. Participants' mean age 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm3; 89% on antiretroviral therapy. 156 (35%)...
To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens.NNRTI-naive were included who started treatment with nevirapine (NVP) or efavirenz (EFV) test results available at time of initiation (baseline). Virological failure was defined as two consecutive values > 500 copies/ml after the regimen. Cox models used to investigate (the first values).A total 759 (13%...
Background: We determined factors associated with self-reported decline in activities of daily living (ADLs) and symptoms cognitive impairment HIV positive adults 5 European clinics. Methods: HIV+ underwent computerized pen-and-paper neuropsychological tests questionnaires ADLs. considered function domains, psychosocial factors, clinical parameters as potentially symptoms. Separate regression analyses were used to determine a ADL (defined affecting ≥2 ADLs attributed difficulties) frequency...
BackgroundAdequate identification and testing of people at risk for HIV is fundamental the care continuum. A key strategy to improve timely indicator condition (IC) guided testing.AimTo evaluate uptake recommendations in IC-specific guidelines European countries.MethodsBetween 2019 2021, experts reviewed guideline databases identify all national 62 ICs. The proportion IC recommending was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement 90-90-90 goals...
There is currently no evidence suggesting that COVID-19 takes a different course in HIV-positive patients on antiretroviral treatment compared to the general population. However, little known about relation between specific HIV-related factors and severity of disease. We performed retrospective analysis cases collected through an on-line survey distributed by Euroguidelines Central Eastern Europe Network Group. In statistical analyses characteristics patients, asymptomatic/moderate...
Abstract Background Early diagnosis of tuberculosis (TB) is important to reduce transmission, morbidity and mortality in people living with HIV (PLWH). Methods PLWH a TB were enrolled from clinics Eastern Europe followed until 24 months. Delayed was defined as duration symptoms (cough, weight-loss or fever) for ≥ 1 month before diagnosis. Risk factors delayed assessed using multivariable logistic regression. The effect on Kaplan–Meier estimates Cox models. Findings 480/740 patients (64.9%;...
Background Liver damage associated with hepatitis C (HCV) may influence the likelihood of experiencing discontinuation due to toxicities or patient/physician choice (TOXPC) in patients taking combination antiretroviral therapy (cART). Little information address this concern is available from clinical trials as HCV are often excluded. Aims To compare incidence rates TOXPC specific antiretrovial drugs without HCV. Patients/methods A total 4929 EuroSIDA under follow-up January 1999 on a...
Following the introduction of direct-acting antiviral therapy in 2013, WHO launched first Global Health Sector Strategy on Viral Hepatitis. We describe a hepatitis C virus (HCV) cascade care people with HIV (PWH) across Europe terms reaching elimination targets diagnosing 90% and treating 80% HCV-infected individuals.HIV/HCV-coinfected participants EuroSIDA cohort under prospective follow-up at October 1, 2019, were described using nine-stage care. Care cascades constructed Europe, regional...
(1) Background: Viral hepatitis C (HCV) and viral B (HBV) are common co-infections in people living with HIV (PLWH). All PLWH should be vaccinated against HBV A (HAV) treated for HCV. We aimed to compare testing, prophylaxis treatment of Central Eastern Europe (CEE) 2019 2022. (2) Methods: Data was collected through two on-line surveys conducted 2022 among 18 countries the Euroguidelines CEE (ECEE) Network Group. (3) Results: In all standard care screen HCV both years; screening HAV routine...
Estimating the prevalence of accumulated HIV drug resistance in patients receiving antiretroviral therapy (ART) is difficult due to lack testing at all occasions virological failure and with undetectable viral load. A method estimate this for 6498 EuroSIDA who were under follow-up on ART 1 July 2008 was therefore developed by imputing data no prior test results, based probability detecting tested similar profiles.Using results available, predicted intermediate/high-level specific classes...
Objectives. The study aimed at describing characteristics and outcome of tuberculous meningitis (TBM) in HIV-positive patients comparing these parameters with those extrapulmonary TB (TBEP) pulmonary (TBP). Methods. Kaplan-Meier estimation Poisson regression models were used to assess the mortality following diagnosis evaluate potential prognostic factors for 3 groups separately. Results. A total 100 TBM, 601 TBEP, 371 TBP included. Patients TBM had lower CD4 cell counts only 17.0% received...
Objectives Pre‐exposure prophylaxis (PrEP) for HIV infection is an important intervention control of the epidemic. The incidence increasing in countries Central and Eastern Europe (CEE). Therefore, we investigated change PrEP use CEE over time. Methods Euroguidelines (ECEE) Network Group was initiated February 2016 to compare standards care viral hepatitis infections CEE. Data on access were collected from 23 through online surveys May–June 2017 (76 respondents) November 2018–May 2019 (28...
Abstract Introduction Data on safety and effectiveness of RPV from the real-world setting as well comparisons with other NNRTIs such efavirenz (EFV) remain scarce. Methods Participants EuroSIDA were included if they had started a RPV- or an EFV-containing regimen over November 2011-December 2017. Statistical testing was conducted using non-parametric Mann–Whitney U test Chi-square test. A logistic regression model used to compare participants’ characteristics by treatment group. Kaplan–Meier...
Abstract Introduction In the last decade, substantial differences in epidemiology of, antiretroviral therapy (ART) for, cascade of care and support to people with HIV vulnerable populations have been observed between countries Western Europe, Central Europe (CE) Eastern (EE). The aim this study was use a survey explore whether ART availability therapies evolved CE EE according European guidelines. Methods Euroguidelines (ECEE) Network Group conducted two identical multicentre cross‐sectional...
Abstract Background There is currently no evidence suggesting that COVID-19 takes a different course in HIV-positive patients on antiretroviral treatment compared to the general population. However, little known about relation between specific HIV-related factors and severity of disease. Methods We performed retrospective analysis cases collected through an on-line survey distributed by Euroguidelines Central Eastern Europe Network Group. In statistical analyses characteristics...
Introduction: The COVID-19 pandemic has been challenging time for medical care, especially in the field of infectious diseases (ID), but it also provided an opportunity to introduce new solutions HIV management. Here, we investigated changes service provision across Central and Eastern European (CEE) countries before after outbreak. Methods: Euroguidelines Europe Network Group consists experts ID from 24 within CEE region. Between 11 September 29 2021, group produced on-line survey,...